Abstract
Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Current Pharmaceutical Design
Title: Lipid Management for the Prevention of Cardiovascular Disease
Volume: 17 Issue: 9
Author(s): Juergen R. Schaefer
Affiliation:
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Abstract: Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Export Options
About this article
Cite this article as:
R. Schaefer Juergen, Lipid Management for the Prevention of Cardiovascular Disease, Current Pharmaceutical Design 2011; 17 (9) . https://dx.doi.org/10.2174/138161211795428849
DOI https://dx.doi.org/10.2174/138161211795428849 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Determinants of Paraoxonase 1 Status: Genes, Drugs and Nutrition
Current Medicinal Chemistry Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets
Current Pharmaceutical Design Anti-Vascular Endothelial Growth Factor Treatment in Retinal Vein Occlusions
Current Drug Therapy Gene-Gene and Gene-Environment Interplay Represent Specific Susceptibility for Different Types of Ischaemic Stroke and Leukoaraiosis
Current Medicinal Chemistry RAGE and its Ligands in Retinal Disease
Current Molecular Medicine Challenges in Vascular Repair by Endothelial Progenitor Cells in Diabetic Patients
Cardiovascular & Hematological Disorders-Drug Targets Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
Current Pharmaceutical Design Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology The Flavin-Containing Monoooxygenases (FMOs): Genetic Variation and its Consequences for the Metabolism of Therapeutic Drugs
Current Pharmacogenomics Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years
Current Vascular Pharmacology TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Structure Activity Relationship Studies of Gymnemic Acid Analogues for Antidiabetic Activity Targeting PPARγ
Current Computer-Aided Drug Design HDL - Cholesterol: The New Target for Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Multi-scale LBP and SVM Classification to Identify Diabetic Retinopathy in Lesions
Current Medical Imaging Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds The Effects of Angiotensin II Signaling Blockade on Platelet Activity in Subjects with Hypertension
Current Hypertension Reviews